Tandem Diabetes Care (TNDM) Operating Leases (2019 - 2026)

Tandem Diabetes Care's Operating Leases history runs 8 years deep, the most recent figure standing at $133.0 million for Q1 2026.

• Quarterly Operating Leases rose 8.06% year-over-year to $133.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.0 million (up 8.06% YoY) and the FY2025 annual result came in at $115.0 million, up 8.03% from the prior year.
• Operating Leases was $133.0 million for Q1 2026 at Tandem Diabetes Care, up from $115.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $139.9 million in Q2 2025 and bottomed at $3.0 million in Q2 2022.
• A 5-year average of $113.7 million and a median of $116.0 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases tumbled 89.04% — and 2023, when it soared 3846.67%.
• Tandem Diabetes Care's Operating Leases stood at $123.5 million in 2022, then declined by 8.06% to $113.6 million in 2023, then dropped by 6.3% to $106.4 million in 2024, then rose by 8.03% to $115.0 million in 2025, then increased by 15.66% to $133.0 million in 2026.
• Business Quant data shows TNDM's Operating Leases at $133.0 million in Q1 2026, $115.0 million in Q4 2025, and $139.7 million in Q3 2025.